---
title: "Brendan Smith Reiterates Buy on AbSci, Citing Emerging PRLR Franchise and Multiple Upcoming Clinical Catalysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285653707.md"
description: "TD Cowen analyst Brendan Smith has reiterated a Buy rating on AbSci (ABSI) stock, citing the company's emerging prolactin receptor franchise and upcoming clinical catalysts. He emphasizes the strategic flexibility provided by the new ABS-202 antibody and the ongoing Phase 1/2a study for ABS-201, which shows promising results. Smith believes that upcoming data readouts in 2026 and early 2027 will significantly enhance the stock's value. H.C. Wainwright also maintains a Buy rating with an $8.00 price target."
datetime: "2026-05-08T02:25:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285653707.md)
  - [en](https://longbridge.com/en/news/285653707.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285653707.md)
---

# Brendan Smith Reiterates Buy on AbSci, Citing Emerging PRLR Franchise and Multiple Upcoming Clinical Catalysts

TD Cowen analyst Brendan Smith has maintained their bullish stance on ABSI stock, giving a Buy rating on April 28.

Brendan Smith has given his Buy rating due to a combination of factors related to AbSci’s emerging prolactin receptor franchise and near-term clinical catalysts. He highlights that the newly introduced ABS-202, a second anti-PRLR antibody aimed at an undisclosed immunology indication, broadens the company’s strategic flexibility across multiple disease settings while enhancing pricing and market positioning options.

Smith also notes that management sees the PRLR platform as widely applicable, complementing lead asset ABS-201 and enabling AbSci to address different market sizes using its generative AI–powered discovery engine. He underscores that the ongoing Phase 1/2a study for ABS-201 has completed single-ascending-dose cohorts with encouraging tolerability and pharmacokinetics, and that upcoming data readouts in Q2, the second half of 2026, and early 2027 represent meaningful value inflection points that support a favorable risk-reward profile.

In another report released on April 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.

### Related Stocks

- [ABSI.US](https://longbridge.com/en/quote/ABSI.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)